The stock price of Aquestive Therapeutics Inc (NASDAQ: AQST) has dropped by -4.25 compared to previous close of 3.41. Despite this, the company has seen a fall of -8.54% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-08 that Aquestive Therapeutics’ Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis, with NDA decision expected imminently. Anaphylm’s advantages—wallet portability, rapid onset, and high patient/provider preference—position it to capture significant share of a $2B U.S. market. My risk-adjusted DCF analysis values AQST at $5/share ( at just 10% market share), indicating the stock is undervalued at current levels.
Is It Worth Investing in Aquestive Therapeutics Inc (NASDAQ: AQST) Right Now?
Moreover, the 36-month beta value for AQST is 1.94. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AQST is 91.68M and currently, short sellers hold a 12.15% of that float. On June 12, 2025, AQST’s average trading volume was 1.51M shares.
AQST’s Market Performance
The stock of Aquestive Therapeutics Inc (AQST) has seen a -8.54% decrease in the past week, with a 42.58% rise in the past month, and a 20.04% gain in the past quarter. The volatility ratio for the week is 2.59%, and the volatility levels for the past 30 days are at 4.67% for AQST. The simple moving average for the past 20 days is 13.34% for AQST’s stock, with a -11.22% simple moving average for the past 200 days.
Analysts’ Opinion of AQST
Many brokerage firms have already submitted their reports for AQST stocks, with Oppenheimer repeating the rating for AQST by listing it as a “Outperform.” The predicted price for AQST in the upcoming period, according to Oppenheimer is $7 based on the research report published on June 02, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AQST reach a price target of $17. The rating they have provided for AQST stocks is “Overweight” according to the report published on December 17th, 2024.
Leerink Partners gave a rating of “Outperform” to AQST, setting the target price at $8 in the report published on May 10th of the previous year.
AQST Trading at 17.94% from the 50-Day Moving Average
After a stumble in the market that brought AQST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.71% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AQST starting from Jung Cassie, who sale 44 shares at the price of $4.87 back on Nov 26 ’24. After this action, Jung Cassie now owns 0 shares of Aquestive Therapeutics Inc, valued at $214 using the latest closing price.
Stock Fundamentals for AQST
Current profitability levels for the company are sitting at:
- -0.76 for the present operating margin
- 0.68 for the gross margin
The net margin for Aquestive Therapeutics Inc stands at -1.0. The total capital return value is set at -0.49.
Based on Aquestive Therapeutics Inc (AQST), the company’s capital structure generated -1.8 points at debt to capital in total, while cash flow to debt ratio is standing at -1.25. The debt to equity ratio resting at -0.64. The interest coverage ratio of the stock is -2.44.
Currently, EBITDA for the company is -26.62 million with net debt to EBITDA at 0.84. When we switch over and look at the enterprise to sales, we see a ratio of 5.38. The receivables turnover for the company is 5.19for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.87.
Conclusion
To wrap up, the performance of Aquestive Therapeutics Inc (AQST) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
